Nevirapin Hormosan (Nevirapine)

Nevirapine, the active ingredient in Nevirapin Hormosan, is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It is employed in the treatment of HIV-1 infection, helping to suppress viral replication in adults and adolescents. Nevirapin Hormosan is manufactured under EU GMP guidelines, ensuring batch consistency and patient safety. GNH USA supplies Nevirapin Hormosan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Nevirapine is an antiretroviral medication that targets the HIV-1 replication pathway.

- HIV-1 infection (adults): reduces viral load and helps restore immune function in infected individuals. - HIV-1 infection (children): contributes to viral suppression and immune recovery when used in pediatric combination therapy. - Prevention of mother-to-child transmission: lowers the risk of vertical transmission when administered to pregnant women living with HIV.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions that may be itchy. - Nausea: occasional stomach discomfort or queasiness. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate head pain. - Elevated liver enzymes: mild increases detected in routine labs. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction with blistering and detachment. - Toxic epidermal necrolysis: life‑threatening widespread skin loss. - Severe hepatotoxicity: marked liver injury that can lead to failure. - Hypersensitivity reactions: systemic allergic responses including fever and organ involvement. - Hepatic failure: acute loss of liver function requiring urgent care.

Nevirapine requires careful monitoring and patient counseling before and during therapy. - Liver monitoring: obtain baseline liver function tests and repeat regularly. - Rash monitoring: inspect skin for any new rash and discontinue if severe. - Hepatic disease caution: avoid use in patients with moderate to severe pre‑existing liver disease. - Pregnancy caution: assess risk‑benefit ratio; use only when benefits outweigh potential fetal risks. - Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Nevirapine can interact with several drug classes, affecting its efficacy or safety.

Major Interactions (Avoid): - Rifampin: strong enzyme inducer that markedly reduces nevirapine plasma levels. - Carbamazepine, phenytoin, St. John's wort: potent CYP3A4 inducers that may compromise antiviral effect.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., ritonavir): may increase nevirapine concentrations and risk of toxicity. - Hormonal contraceptives: nevirapine can lower contraceptive effectiveness; additional methods advised. - Warfarin: may alter anticoagulant control; monitor INR more frequently.